Knight Therapeutics Inc KHTRF

Primary Symbol: T.GUD

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > CPH acquired global rights to lice & scabies treatment

<< Previous

Bullboard Posts

Next >>

Comment by wofatson Aug 01, 2024 11:48am

128 Views

Post# 36158395

RE:RE:CPH acquired global rights to lice & scabies treatment

You did mean except for this one over the last 3 years if you were astute enough to buy between Dec.2020 and Dec2023. Just sayin .
I do remember you posting you not own any Knight though .

Second quarter results coming next week There still is no volume on the stock .A few shares move the stock up and down and distort it . I am still picking away.